Pathological complete response of HER2-positive breast cancer to trastuzumab and chemotherapy can be predicted by HSD17B4 methylation

Complete Response ◽

Her2 Positive ◽

Pathological Complete response to neoadjuvant trastuzumab and pertuzumab therapy is dependent on HER2/CEP17 ratio in HER2-positive breast cancer

European Journal of Surgical Oncology ◽

10.1016/j.ejso.2018.10.350 ◽

2019 ◽

Vol 45 (2) ◽

pp. e101

Author(s):

J. Choi ◽

C.W. Jeon ◽

A.L. Kim ◽

S.U. Jung

Keyword(s):

Breast Cancer ◽

Complete Response ◽

Her2 Positive ◽

Pathological Complete Response with Neoadjuvant Trastuzumab Combined with Chemotherapy in HER2 Positive Breast Cancer: A Single Institution Retrospective Analysis from Vietnam

Breast Cancer Targets and Therapy ◽

10.2147/bctt.s268369 ◽

2020 ◽

Vol Volume 12 ◽

pp. 117-122

Author(s):

Huyen Thi Phung ◽

Hoa Thi Nguyen ◽

Tung Van Nguyen ◽

Tai Van Nguyen ◽

Lan Anh Thi Dinh ◽

...

Keyword(s):

Breast Cancer ◽

Retrospective Analysis ◽

Complete Response ◽

Single Institution ◽

Her2 Positive ◽

Abstract S3-03: PAM50 intrinsic subtype as a predictor of pathological complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer: First results of the PAMELA clinical trial

10.1158/1538-7445.sabcs16-s3-03 ◽

2017 ◽

Author(s):

A Prat Aparicio ◽

J Cortes Castan ◽

L Pare ◽

P Galvan ◽

B Bermejo ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Complete Response ◽

Intrinsic Subtype ◽

Her2 Positive ◽

First Results ◽

Abstract P1-03-08: Simultaneous analyses of HER2 gene and protein status can more precisely predict pathological complete response (pCR) to neoadjuvant trastuzumab with chemotherapy in primary HER2-positive breast cancer

10.1158/1538-7445.sabcs16-p1-03-08 ◽

2017 ◽

Author(s):

R Horii ◽

H Nitta ◽

Y Ito ◽

T Iwase ◽

S Ohno ◽

...

Keyword(s):

Breast Cancer ◽

Complete Response ◽

Her2 Gene ◽

Her2 Positive ◽

Protein Status ◽

HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis

Cancer Treatment Reviews ◽

10.1016/j.ctrv.2020.101965 ◽

2020 ◽

Vol 84 ◽

pp. 101965 ◽

Cited By ~ 8

Author(s):

Francesco Schettini ◽

Tomás Pascual ◽

Benedetta Conte ◽

Nuria Chic ◽

Fara Brasó-Maristany ◽

...

Keyword(s):

Breast Cancer ◽

Systematic Review ◽

Meta Analysis ◽

Complete Response ◽

Her2 Positive ◽

HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.509 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 509-509 ◽

Cited By ~ 8

Author(s):

Aleix Prat ◽

Carmine De Angelis ◽

TomÃ¡s Pascual ◽

Carolina Gutierrez ◽

Antonio Llombart-Cussac ◽

...

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Complete Response ◽

Her2 Positive ◽

Combined Analysis ◽

Erbb2 Mrna ◽

P143: Rates of pathological complete response to neoadjuvant pertuzamab in patients with HER2 positive breast cancer

European Journal of Surgical Oncology ◽

10.1016/j.ejso.2020.03.182 ◽

2020 ◽

Vol 46 (6) ◽

pp. e48-e49

Author(s):

Amber Shivarajan ◽

Hiba Fatayer ◽

Nicholas Hobbs ◽

Sami Titi ◽

Nabila Nasir

Keyword(s):

Breast Cancer ◽

Complete Response ◽

Her2 Positive ◽

Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is dependent on HER2/CEP17 ratio in HER2-positive breast cancer

European Journal of Cancer ◽

10.1016/s0959-8049(20)30685-7 ◽

2020 ◽

Vol 138 ◽

pp. S59

Author(s):

S. Jung ◽

C.W. Jeon ◽

J. Choi ◽

D. Hyun ◽

H. Lee ◽

...

Keyword(s):

Breast Cancer ◽

Complete Response ◽

Her2 Positive ◽

Nuclear Gli1 expression is associated with pathological complete response and event-free survival in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant therapy

Tumor Biology ◽

10.1007/s13277-015-4325-y ◽

2015 ◽

Vol 37 (4) ◽

pp. 4873-4881 ◽

Cited By ~ 3

Author(s):

Shiwei Liu ◽

Xuening Duan ◽

Ling Xu ◽

Jingming Ye ◽

Yuanjia Cheng ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Therapy ◽

Complete Response ◽

Event Free Survival ◽

Her2 Positive ◽

Free Survival ◽

Gli1 Expression ◽

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

Annals of Oncology ◽

10.1093/annonc/mdw197 ◽

2016 ◽

Vol 27 (8) ◽

pp. 1519-1525 ◽

Cited By ~ 81

Author(s):

S. Loibl ◽

I. Majewski ◽

V. Guarneri ◽

V. Nekljudova ◽

E. Holmes ◽

...

Keyword(s):

Breast Cancer ◽

Response Rates ◽

Complete Response ◽

Pooled Analysis ◽

Her2 Positive ◽

Pik3ca Mutations ◽

Prospective Trials ◽